GARRETT L WALSH to Epirubicin
This is a "connection" page, showing publications GARRETT L WALSH has written about Epirubicin.
Connection Strength
0.079
-
A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. Br J Cancer. 2009 Jan 27; 100(2):305-10.
Score: 0.021
-
Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol. 2008 Nov; 19(11):1847-52.
Score: 0.020
-
A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer. Ann Oncol. 2002 Jun; 13(6):889-94.
Score: 0.013
-
Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. J Clin Oncol. 1998 Apr; 16(4):1350-7.
Score: 0.010
-
High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol. 1995 Feb; 13(2):424-9.
Score: 0.008
-
Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. J Clin Oncol. 1994 Jun; 12(6):1259-65.
Score: 0.007